The FDA has approved an immunotherapeutic for certain patients with these cancers who had their cancer completely resected and received chemoradiotherapy before surgery. The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic nivolumab...
The FDA has granted accelerated approval to an immunotherapeutic to be used in combination with a targeted therapeutic and chemotherapy to treat certain patients with gastric or gastroesophageal junction adenocarcinomas. The U.S. Food and...
The FDA has approved the targeted therapeutic loncastuximab tesirine-lpyl to treat certain adult patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta) to...
The FDA has granted accelerated approval to an immunotherapy to treat certain adult patients with endometrial cancer that tests positive for a specific biomarker. The U.S. Food and Drug Administration (FDA) has granted accelerated...
The FDA has approved an immunotherapeutic in combination with chemotherapy to treat certain patients with gastric cancer, gastroesophageal junction cancer, and a common form of esophageal cancer. The U.S. Food and Drug Administration (FDA)...
The FDA granted accelerated approval to the targeted therapeutic sacituzumab govitecan to treat certain patients with the most common form of bladder cancer. The U.S. Food and Drug Administration (FDA) recently granted accelerated approval...
The FDA approved the first CAR T-cell therapy to treat certain adult patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved idecabtagene vicleucel (Abecma) to treat adult patients with relapsed...
the immunotherapeutic pembrolizumab in combination with chemotherapy WAS APPROVED to treat certain adult patients with esophageal cancer. The U.S. Food and Drug Administration (FDA) recently approved the immune checkpoint inhibitor pembrolizumab (Keytruda) in combination...
The FDA approved the molecularly targeted therapeutic tivozanib to treat certain adult patients with the most common type of kidney cancer. The U.S. Food and Drug Administration (FDA) has approved tivozanib (Fotivda) to treat...
The FDA granted accelerated approval to a CAR T-cell therapy for certain adult patients with follicular lymphoma, a common type of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) granted accelerated approval to...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now